Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of sapablursen when added to the current standard of care for treating Polycythemia Vera PV. This Phase 3 trial involves participants who depend on phlebotomy and meet specific diagnostic criteria for PV. The study aims to assess how well sapablursen controls the need for phlebotomy and other health measures in this condition. The study has three parts Part 1a is a 32-week period where participants receive either sapablursen or a placebo in a double-blind manner. In Part 1b, participants receive open-label sapablursen for 124 weeks following the initial phase. There is also a long-term extension phase allowing treatment for up to 156 weeks. Sapablursen and placebo are given by subcutaneous injection. Participants will undergo various assessments, including monitoring of hematocrit levels, number of phlebotomies, and patient-reported symptoms such as fatigue and myelofibrosis symptoms. The main outcome is the percentage of participants who do not need phlebotomy between weeks 20 and 32. Safety and effectiveness are followed throughout the study, which may last up to nearly five years from start to completion.
Actively Recruiting
Researchers are evaluating the pharmacokinetics similarity, safety, and immune response between Bmab1700, an intended biosimilar to nivolumab, and the United States-licensed Opdivo in participants who have had complete surgical removal of melanoma. The study focuses on adults with Stage IIB, IIC, III, or IV melanoma that has been fully resected. This phase 1 trial aims to compare these treatments as adjuvant monotherapy after surgery to understand their behavior in the body and their safety. Participants are randomly assigned to one of two groups. In the first 24 weeks Double-Blind Treatment Period, they receive intravenous infusions of either Bmab1700 or Opdivo every four weeks until disease relapse, unacceptable toxicity, or Week 20, whichever comes first. After Week 24, participants who continue in the study enter an Open-Label Treatment Period where all receive Bmab1700 every four weeks until Week 48, followed by an end-of-study visit at Week 52. Throughout the study, participants undergo regular assessments including blood sampling for drug concentration and immune response measures, monitoring for adverse events, and physical exams. Researchers measure drug levels over time, immune antibody development, and safety outcomes to evaluate the treatments. The total participation lasts up to 52 weeks, with careful monitoring to track treatment effects and participant health.
Actively Recruiting
Researchers are evaluating trastuzumab deruxtecan T-DXd for adults with unresectable or metastatic breast cancer that is either HER2-low or HER2 IHC 0. This includes patients with hormone receptor-negative and hormone receptor-positive types. The study aims to assess the safety and effectiveness of T-DXd, focusing on how long patients benefit from this treatment before needing the next anticancer therapy. Participants receive T-DXd intravenously at a dose of 5.4 mgkg on the first day of each 21-day cycle. Treatment continues until disease progression, unacceptable side effects, other criteria for stopping, or two years after the first dose. The study includes four groups based on hormone receptor status and HER2 classification, with participants having had one to two prior treatments for metastatic breast cancer. During the study, participants will have regular assessments including imaging scans to measure tumors, blood tests to monitor organ function, and questionnaires to evaluate quality of life. Researchers will track the time to next treatment, progression-free survival, response rates, adverse events, and changes in patient-reported outcomes for up to 24 months. Safety monitoring and close follow-up will support participant well-being throughout the trial.